Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Gene therapeutics developer bluebird nets $108mm through its IPO

Executive Summary

Bluebird bio Inc., developer of gene transfer therapeutics, has netted $108mm through its initial public offering of 6.8mm common shares (including the overallotment) at $17. Just days before the final pricing, it had proposed selling 5mm shares between $14-16.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register